Personalized medicine is the future of healthcare, and artificial intelligence will play a big role.
Treatment can no longer be one dimensional.
Medical device companies will be driven to evolve their business models to a more patient/consumer-centric approach.
After a series of delays and false starts, EMA is now progressing its ISO IDMP agenda with firm intent. The first implementation guide is out now for consultation, to be followed by a second actionable version by next year. Life sciences companies targeting Europe will have a year to comply with all the measures—but this will be a lot of work.
A recent report from Frost & Sullivan anticipates strong market growth but also points to opportunity for more vulnerabilities.